RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerN/A

Registered title, quoted from ClinicalTrials.gov

Clinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced Pain

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Peking University People's Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University People's Hospital北京大学人民医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07593365, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: women only

    Registered eligibility fields

  2. Patients with pathologically confirmed stage I-III primary breast cancer;

    Inclusion criterion 2

  3. Patients who have received aromatase inhibitor therapy for more than 30 days and are expected to continue treatment for more than 1 year;

    Inclusion criterion 5

    Pain relief rate of less than 50% after taVNS treatment and a lower peripheral blood Treg count than before treatment.

    Inclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07593365, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female participants aged over 18 years;
  • Patients with pathologically confirmed stage I-III primary breast cancer;
  • Patients who have recovered from systemic symptoms related to surgery, radiotherapy, or chemotherapy;
  • Patients with estrogen receptor- and/or progesterone receptor-positive breast cancer who are receiving aromatase inhibitor therapy and have aromatase inhibitor-related musculoskeletal pain, with a score greater than 3 on the Worst Pain item of the Brief Pain Inventory (BPI-WP);
  • Patients who have received aromatase inhibitor therapy for more than 30 days and are expected to continue treatment for more than 1 year;
  • Patients who voluntarily agree to participate in this study and sign the informed consent form.

For participants receiving combined IL-2 treatment, the following additional criterion applies:

  • Pain relief rate of less than 50% after taVNS treatment and a lower peripheral blood Treg count than before treatment.

Exclusion Criteria:

  • Patients with advanced breast cancer;
  • Patients with other significant organ dysfunction, such as major cardiovascular disease, diabetes mellitus, or hyperthyroidism;
  • Patients with other cancers;
  • Patients with a history of fracture or surgery around the painful joint area within the past 6 months;
  • Patients currently receiving corticosteroids or opioid therapy;
  • Patients with contraindications to vagus nerve stimulation;
  • Patients who are unable to communicate normally, such as those with cognitive impairment or hearing impairment;
  • Patients who have participated in another clinical trial within the past 1 month.

For participants receiving combined IL-2 treatment, the following additional exclusion criteria apply:

  • Severe cardiac or renal disease, or hematologic disease;
  • Previous IL-2-related toxic reaction or allergy;
  • Use of other biologic agents or immunosuppressive drugs within the past 1 month;
  • Any other condition that the investigator considers unsuitable for study participation.

Quoted from ClinicalTrials.gov, NCT07593365, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07593365, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07593365